{"id":"radicava-ors","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL290916","moleculeType":"Small molecule","molecularWeight":"174.20"},"_dailymed":{"setId":"0ce2c1c4-2a40-485c-b7cb-96a9b85d9d11","title":"RADICAVA (EDARAVONE) INJECTION RADICAVA ORS (EDARAVONE) KIT [TANABE PHARMA AMERICA, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Edaravone is a small-molecule antioxidant that crosses the blood-brain barrier and selectively scavenges free radicals, particularly hydroxyl radicals, which are implicated in neuronal damage in amyotrophic lateral sclerosis (ALS). By reducing oxidative stress and neuroinflammation, it may slow the rate of motor neuron degeneration. The ORS (oral suspension) formulation provides an oral alternative to the intravenous edaravone (Radicava IV).","oneSentence":"Radicava ORS is an oral formulation of edaravone that acts as a free radical scavenger to reduce oxidative stress in motor neurons.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T05:25:16.556Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Amyotrophic lateral sclerosis (ALS)"}]},"trialDetails":[{"nctId":"NCT06107205","phase":"PHASE1","title":"Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shanghai Auzone Biological Technology Co., Ltd.","startDate":"2023-11-07","conditions":"Healthy Adult Subjects","enrollment":29},{"nctId":"NCT04259255","phase":"","title":"Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)","status":"UNKNOWN","sponsor":"Tanabe Pharma America, Inc.","startDate":"2019-10-21","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20220512","type":"ORIG","sponsor":"KK BCJ-94","applicationNumber":"NDA215446"}],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Edaravone ORS"],"phase":"marketed","status":"active","brandName":"Radicava ORS","genericName":"Radicava ORS","companyName":"Shanghai Auzone Biological Technology Co., Ltd.","companyId":"shanghai-auzone-biological-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Radicava ORS is an oral formulation of edaravone that acts as a free radical scavenger to reduce oxidative stress in motor neurons. Used for Amyotrophic lateral sclerosis (ALS).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}